Optimised lymphoscintigraphy in pregnant patients with breast cancer is safe [3]

Annals of Oncology

Volumn 16, Issue 4, 2005, Pages 674-675

  Paganelli, G ^a   Ferrari, M ^a   Cremonesi, M ^a   Gentilini, O ^a   Trifiro G ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOPHARMACEUTICAL AGENT;

BREAST CANCER; FEMALE; GESTATION PERIOD; HUMAN; LETTER; LYMPHOSCINTIGRAPHY; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION HAZARD; RISK ASSESSMENT;

EID: 18144416570     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi105     Document Type: Letter

References (7)

1. Gentilini O, Cremonesi M, Trifirò G et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol 2004; 15: 1348-1351.
2. Morita ET, Chang J, Leong SP. Principles and controversies in lymphoscintigraphy with emphasis on breast cancer. Surg Clin North Am 2000; 80: 1721-1739.
3. Nicklas A, Baker M. Imaging strategies in pregnant cancer patients. Semin Oncol 2000; 27: 623-632.
4. Russell JR, Stabin MG, Sparks RB. Placental transfer of radiopharmaceuticals and dosimetry in pregnancy. Health Physics 1997; 73: 747-755.
5. Steenvoorde P, Pauwels E, Harding LK, Bourguignon M, Marière B, Broerse J. Diagnostic nuclear medicine and risk for the fetus. Eur J Nucl Med 1998; 25: 193-199.
6. International Commission on Radiological Protection. Pregnancy and Medical Radiation. ICRP Publication 84. Annals of the ICRP, 2000. New York: Pergamon Press.
7. International Commission on Radiological Protection. Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. Annals of the ICRP Volume 21 No. 1-3, 1991.